
Isabl
Cancer tests based on whole genome and transcriptome data.
- Founded
- 2020
- Status
- Active
- Stage
- Early
- Team size
- 5
- Location
- New York City, NY, USA; New York
- Category
- Biotech & Drug Discovery
- Sector
- Diagnostics
About Isabl
Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.
Federal research funding
2 NIH awards totalling $2,033,377, FY2023 to FY2024.
- Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform
Source: NIH RePORTER.
Company data compiled and maintained by Healthcare Discovery.
